ATE232109T1 - Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung - Google Patents

Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung

Info

Publication number
ATE232109T1
ATE232109T1 AT94925121T AT94925121T ATE232109T1 AT E232109 T1 ATE232109 T1 AT E232109T1 AT 94925121 T AT94925121 T AT 94925121T AT 94925121 T AT94925121 T AT 94925121T AT E232109 T1 ATE232109 T1 AT E232109T1
Authority
AT
Austria
Prior art keywords
muc
tandem repeats
derivatives
peptides
multiple tandem
Prior art date
Application number
AT94925121T
Other languages
English (en)
Inventor
Olivera J Finn
J Darrell Fontenot
Ronald C Montelaro
Original Assignee
Olivera J Finn
J Darrell Fontenot
Ronald C Montelaro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olivera J Finn, J Darrell Fontenot, Ronald C Montelaro filed Critical Olivera J Finn
Application granted granted Critical
Publication of ATE232109T1 publication Critical patent/ATE232109T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94925121T 1993-07-30 1994-07-29 Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung ATE232109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/099,354 US5744144A (en) 1993-07-30 1993-07-30 Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
PCT/US1994/008477 WO1995003825A1 (en) 1993-07-30 1994-07-29 Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ATE232109T1 true ATE232109T1 (de) 2003-02-15

Family

ID=22274597

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925121T ATE232109T1 (de) 1993-07-30 1994-07-29 Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung

Country Status (7)

Country Link
US (2) US5744144A (de)
EP (1) EP0804231B1 (de)
JP (1) JPH09501159A (de)
AT (1) ATE232109T1 (de)
CA (1) CA2167730A1 (de)
DE (1) DE69432109T2 (de)
WO (1) WO1995003825A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
JP4125784B2 (ja) * 1995-10-20 2008-07-30 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 抗原提示細胞により仲介される免疫応答を高めるための組成物および方法
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU2116497A (en) * 1996-01-31 1997-08-22 Population Council, The Multivalent chimeric peptides as microbicides
EP0923605A4 (de) * 1996-03-20 2003-01-02 Sloan Kettering Inst Cancer Mucin enthaltende konjugierte impfstoffe
WO1997035008A1 (en) * 1996-03-21 1997-09-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chimeric polypeptides for tumor antigen vaccines
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
DE69734776T2 (de) * 1996-05-24 2006-08-17 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Fusionsprotein mit multiplen Epitopen
WO1998010783A1 (en) * 1996-09-10 1998-03-19 Biomira Inc. Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
JP2001502907A (ja) * 1996-10-25 2001-03-06 ダナ―ファーバー キャンサー インスティテュート インク． ムチンが介在した免疫調節
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
CA2335749A1 (en) * 1998-06-26 2000-01-06 B. Michael Longenecker Method of detecting t-cell activation
DE69941627D1 (de) * 1998-11-05 2009-12-17 Univ Michigan Für krebs
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19906615A1 (de) * 1999-02-17 2000-09-28 Hanisch Franz Georg Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung
GB9904695D0 (en) * 1999-03-01 1999-04-21 Imp Cancer Res Tech Peptide
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20050019340A1 (en) 2000-10-18 2005-01-27 Nathalie Garcon Vaccines
US20020142047A1 (en) * 2001-01-19 2002-10-03 Johnson Mark E. Microsphere delivery of mucin peptides
WO2002076485A2 (en) 2001-03-27 2002-10-03 Biomira, Inc. Vaccine for modulating between t1 and t2 immune responses
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
EP1383802A4 (de) * 2001-03-30 2005-08-03 Univ California Anti-muc-1-einzelkettenantikörper zum targeting von tumoren
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
EP1436319A2 (de) * 2001-10-18 2004-07-14 Zlatko Ademovic Sich wiederholende motive aus prolinreichen speichelproteinen, mucin und kollagen
AU2002332697A1 (en) * 2001-12-12 2003-06-23 Leon J. Lewandowski Photophoretic auto immune stimulation
AU2003203034A1 (en) * 2002-01-14 2003-07-30 Vertex Pharmaceuticals Incorporated Mucin immobilized chromatography
EP1474432A1 (de) * 2002-02-04 2004-11-10 Biomira Inc. Immunstimulierende, kovalent lipid-modifizierte oligonukleotide
CA2482477A1 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
EP2330113B1 (de) 2002-04-19 2016-06-29 The Governing Council Of The University Of Toronto Immunologisches Verfahren und Zusammensetzungen für die Behandlung der Alzheimer Krankheit
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
CA2898163C (en) * 2002-12-16 2016-10-11 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7696306B2 (en) * 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
CN1902312B (zh) 2003-11-04 2011-02-23 株式会社载体研究所 制备导入了基因的树突细胞的方法
JP4995575B2 (ja) * 2003-11-12 2012-08-08 アメリカ合衆国 乳癌を処置および予防するためのシステム
WO2005046622A2 (en) * 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
US7999071B2 (en) * 2003-12-12 2011-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
TWI395591B (zh) * 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
EP1861426A4 (de) * 2005-02-08 2008-11-12 Queensland Inst Med Res Immunogene moleküle
BRPI0610267B8 (pt) 2005-05-27 2021-07-27 Oncimmune Ltd métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
TWI511738B (zh) * 2005-06-28 2015-12-11 安柯席爾伊恩股份有限公司 以黏液性糖蛋白(ｍｕｃ-１）疫苗治療病人之方法
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP1989326A4 (de) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex-verfolgungstest
US20100167341A1 (en) 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
CA2658266A1 (en) 2006-07-13 2008-01-17 Dnavec Corporation Non-replicating paramyxoviridae virus vector
EP2046812A4 (de) * 2006-07-25 2010-04-14 4G Vaccines Pty Ltd Ein von einem mucin-1- (muc1-) t-zellen-epitop abgeleitetes peptid enthaltender krebsimpfstoff
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
CA2682350A1 (en) * 2007-04-11 2008-10-23 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
US20090124557A1 (en) * 2007-04-16 2009-05-14 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer
EA018201B1 (ru) 2007-05-24 2013-06-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
KR101527260B1 (ko) 2008-11-14 2015-06-08 디나벡크 가부시키가이샤 수상세포의 제조방법
AU2011226992B2 (en) 2010-05-10 2012-03-22 Ascend Biopharmaceuticals Pty Ltd Immunostimulatory and vaccine compositions
AU2012222188A1 (en) 2011-02-24 2013-08-15 Oncothyreon Inc. MUC1 based glycolipopeptide vaccine with adjuvant
US10138271B2 (en) 2012-01-03 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist CTL epitopes of the MUC1 tumor antigen
WO2016105536A2 (en) * 2014-12-23 2016-06-30 University Of Maryland, Baltimore Muc1 decoy peptides for treatment and prevention of bacterial infections
EP3518964A2 (de) 2016-09-28 2019-08-07 Bavarian Nordic A/S Zusammensetzungen und verfahren zur erhöhung der stabilität von transgenen in pockenviren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369816A3 (de) * 1988-11-17 1990-09-12 The University Of Melbourne Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
WO1991008217A1 (en) * 1989-12-05 1991-06-13 The Regents Of The University Of California Human intestinal mucins

Also Published As

Publication number Publication date
DE69432109T2 (de) 2003-11-20
CA2167730A1 (en) 1995-02-09
US5744144A (en) 1998-04-28
EP0804231A4 (de) 1999-08-18
EP0804231B1 (de) 2003-02-05
EP0804231A1 (de) 1997-11-05
US5827666A (en) 1998-10-27
DE69432109D1 (de) 2003-03-13
JPH09501159A (ja) 1997-02-04
WO1995003825A1 (en) 1995-02-09

Similar Documents

Publication Publication Date Title
ATE232109T1 (de) Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
IL124831A0 (en) Ob protein derivatives having prolonged half-life
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
ATE518874T1 (de) Synthetische lipid-a analogen und verwendungen davon
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
IT8449164A1 (it) Composizioni farmaceutiche contenenti sucralfat e procedimento per la loro stabilizzazione
BG102071A (en) Minor molecule inhibitors of rotamase enzymic activity
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
FI20075338A7 (fi) gp350/220:n ei silmukoivia muutoksia
MY115211A (en) Novel amino acid derivatives, their preparation and use
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
BG104267A (en) Aminoterminally incised rantes as haemokin antagonists
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
CA2201944A1 (en) Analogs of keratinocyte growth factor having enhanced temperature stability
SE9602822D0 (sv) New receptor
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE59410221D1 (de) Rekombinante chladosporium herbarum allergene
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
DE68905097D1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
IL71870A0 (en) Improved steroid ester preparation
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties